Financing ·
Xeris Biopharma Holdings, Inc. completed privately negotiated exchange transactions for its 8.00% Convertible Senior…
XERSXeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. completed privately negotiated exchange transactions for its 8.00% Convertible Senior Notes due 2028, exchanging approximately $28.5 million in aggregate principal amount of the 2828 Notes for approximately 5.0 million shares of common stock and $23 million in cash. Additionally, a holder of $10.5 million in principal amount of the 2828 Notes converted their notes into approximately 3.6 million shares of common stock. Following these transactions, no 2028 Notes remain outstanding. Xeris Biopharma Holdings, Inc. is a biopharma company that develops and commercializes biopharmaceutical products.